BioAlliance Pharma appoints Pierre MORGON Chief Operating Officer and Member of the...

BioAlliance Pharma appoints Pierre MORGON Chief Operating Officer and Member of the Management Board

Experienced pharma industry executive brings robust performance
record to hospital specialty pharma company
PARIS--(Business Wire)--
Regulatory News:

BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical
company focused on the treatment of opportunistic infections in cancer
and HIV, today announced that it has strengthened its Management Board
with the appointment of Pierre MORGON as Chief Operating Officer
(COO).

Pierre A. MORGON, 45, PharmD, MS Law, MBA spent 23 years in the
pharmaceutical industry in various positions involving P&L
responsibility, large managerial scopes, staff and line accountability
and international experience.

He joins from Schering-Plough France, where he managed the primary
care operations in France for two years and the partnership with MSD.
From 2004 to 2006, he was VP Hospital Operations at Bristol Myers
Squibb. From 2003 to 2004, he served as General Manager of Yamanouchi
Pharma France and prepared the merger with Fujisawa.

Prior to these positions in Operations, Pierre A. MORGON acquired
a wide experience in spearheading the launch of products in hospital,
retail and vaccine markets and in developing new business models. He
served from 1998 to 2003 as VP International Marketing and VP Global
Product Marketing at Aventis Pasteur. From 1993 to 1998, he was
Marketing Director, USA-Canada-Japan at Synthelabo, successfully
launching Ambien in the US and Kerlone in Japan and managing the joint
venture with local partners. From 1988 to 1993, he served in Product
and Group Product Management positions at Synthelabo and at
ICI-Pharma.

Pierre A. MORGON is a member of the Management Centre Europe Sales
& Marketing Council, and he is a lecturer in pharmaceutical industry
seminars and in business schools. He received his Doctorate of
Pharmacy from the University of Lyon in 1985, his Masters in Business
Law from the Lyon Law School in 1986 and his MBA from ESSEC in Paris
in 1998. He is also an alumnus of INSEAD, IMD and MCE executive
programs.

Dr Dominique COSTANTINI, Co-Founder, President and CEO of
BioAlliance Pharma and Dr Gilles AVENARD, Co-Founder and Chief
Operating Officer, explained "As COO, Pierre MORGON will focus on the
commercial operations across all territories and oversee the execution
of the pricing and product launch strategy by the partners. He will
drive the expansion into new countries, bring his expertise to the
identification of additional business partners and contribute to the
design of the company's strategy. Pierre will also contribute to the
interface with the financial community. We are delighted to add Pierre
to the Management Board and we are looking forward to this next phase
of the development of BioAlliance."

About BioAlliance Pharma

BioAlliance Pharma SA is a specialty pharmaceutical company
focused on the treatment of opportunistic infections in cancer and
HIV. The company develops and commercializes innovative products which
address drug resistance issues. BioAlliance Pharma has launched its
first portfolio product (Loramyc(R)) in France and, more recently, in
the UK, Germany and Denmark, and has already received European
Marketing Authorizations in Belgium and Luxemburg. The product has
also completed a pivotal Phase III clinical trial in the United States
in oropharyngeal candidiasis. The company is also performing a Phase
III trial in labial herpes with acyclovir Lauriad(R) (which is based
on the same Lauriad(R) muco-adhesive technology as Loramyc(R),
enabling targeted release at the disease site). BioAlliance Pharma
also has a second technology (the Transdrug(R) nanoparticle
technology, designed specifically for intracellular targeting) and,
furthermore, is developing a new therapeutic entities program in
oncology and infectious disease. BioAlliance Pharma has established
several strategic alliances for commercializing Loramyc(R), with
agreements in 2007 for Europe (with the SpeBio joint venture) and the
United States (with Par Pharmaceutical) and in 2008 for Asia (Korea,
Malaysia, Singapore and Taiwan with Handok Pharmaceuticals and then
China with NovaMed). In May and August 2008, the company expanded its
product portfolio by acquiring the Europe commercial rights to,
respectively, ondansetron Oral Spray (OS) from NovaDel Pharma Inc.
(Amex: NVD) and ondansetron RapidFilm(TM) from APR/Labtec. For more
information, visit BioAlliance Pharma's website at
www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of BioAlliance Pharma
SA to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
BioAlliance Pharma SA is providing this communication as of this date
and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements
of BioAlliance Pharma SA to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the reference document approved by
the AMF on April 11 2008 under the number R. 08-021, which is
available on the AMF website (http://www.amf-france.org) or on
BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com

Copyright Business Wire 2008